Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

A CLL caregiver shares the reality of CAR T-cell therapy and why support for those who play this critical role will be essential to ensure access to these therapies.

A consensus definition of high genomic complexity in chronic lymphocytic leukemia may be less important than analyzing the contributions of individual biomarkers.

A French real-world study of 282 patients with CLL identified 2 distinct treatment profiles shaped by age, genetics, and logistics—not trial data alone.

There was comparable 12-month fitness and functional outcomes in lymphoma survivors, suggesting a scalable option to expand access to cardio-oncology care.

A new meta-analysis finds patients who have CLL with “borderline” IGHV status have intermediate outcomes, supporting the need for more precise risk classification.

A real-world study has found that personalizing ibrutinib doses based on patient health does not compromise survival outcomes in chronic lymphocytic leukemia (CLL).

Zanubrutinib had low discontinuation and atrial fibrillation rates in R/R CLL/SLL, supporting tolerability over first-generation BTK inhibitors.

Low serum IgE levels were independently associated with nearly double the risk of developing CLL in a retrospective cohort study of 118,740 adults.

It may be possible to detect Richter transformation (RT) years before it actually occurs in patients with chronic or small lymphocytic leukemia, research indicates.

Population data reveal serious infections drive CLL hospital costs, clarifying morbidity and mortality in the hematologic cancer and its true economic consequences.

Patients with chronic or small lymphocytic leukemia now have a variety of treatment options, although a new report found not every patient was presented with multiple options.

Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and chemotoxicity.

The findings bolster the case for using Bruton tyrosine kinase inhibitors in the treatment of Richter syndrome.

Domain Adaptation leverages lymphoma EHRs to better predict infection risk from treatment-related immune suppression in CLL, boosting Matthews correlation coefficient.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

A new review highlights the potential to develop ways to better anticipate and treat Richter transformation in patients with chronic lymphocytic leukemia.

Mitochondrial DNA heteroplasmy is independently associated with an increased risk of CLL, suggesting potential as a novel biomarker for early risk identification.

Bruton tyrosine kinase–based therapies show promising but variable efficacy in Richter transformation, current data suggest.

The FDA approved acalabrutinib and venetoclax, a fixed‑duration all‑oral CLL/SLL first‑line combo, based on phase 3 AMPLIFY trial data.

Data suggest the benefits of zanubrutinib versus acalabrutinib in R/R chronic lymphocytic leukemia were even more pronounced in high-risk cases.

Margaret Krackeler, MD, of Kaiser Permanente Northern California, shares lessons on implementing evidence-based formulary changes for patients with CLL.

Real-world ONCare data show acalabrutinib lowers new-onset HTN, CV events, and discontinuations vs ibrutinib in R/R CLL/SLL.

This new study reveals venetoclax and rituximab effectively treat chronic lymphocytic leukemia, showing high response rates and prolonged progression-free survival.

A review article focused on first-line treatment of chronic lymphocytic leukemia highlights the importance of shared decision-making.

IGHV-unmutated CLL comprises 2 distinct epigenetic subtypes with different B-cell maturation signatures and genetic alterations, a study found.